Traci A Mansfield
Overview
Explore the profile of Traci A Mansfield including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
868
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fioretto P, Mansfield T, Ptaszynska A, Yavin Y, Johnsson E, Parikh S
Drugs Aging
. 2016 Jul;
33(7):511-22.
PMID: 27357173
Objective: To evaluate the 104-week safety of dapagliflozin in older patients with type 2 diabetes mellitus. Methods: Pooled analysis assessing general safety (nine phase III studies ≤104 weeks) and cardiovascular...
2.
Johnsson K, Johnsson E, Mansfield T, Yavin Y, Ptaszynska A, Parikh S
Postgrad Med
. 2016 Feb;
128(4):346-55.
PMID: 26878357
Objective: Dapagliflozin reduces hyperglycemia in type 2 diabetes mellitus (T2DM) and lowers blood pressure, at least in part, secondary to mild diuresis consequent to dapagliflozin-induced glucosuria. While blood-pressure lowering may...
3.
Yavin Y, Mansfield T, Ptaszynska A, Johnsson K, Parikh S, Johnsson E
Diabetes Ther
. 2016 Jan;
7(1):125-37.
PMID: 26758563
Introduction: Hyperkalemia risk is increased in diabetes, particularly in patients with renal impairment or those receiving angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs) or potassium-sparing diuretics. Conversely, other diuretics...
4.
Weber M, Mansfield T, Alessi F, Iqbal N, Parikh S, Ptaszynska A
Blood Press
. 2015 Dec;
25(2):93-103.
PMID: 26623980
Hypertension and type 2 diabetes mellitus (T2DM) are risk factors for cardiovascular disease. Dapagliflozin improves glycemic control and systolic blood pressure (SBP) in T2DM patients. This double-blind phase III study...
5.
Weber M, Mansfield T, Cain V, Iqbal N, Parikh S, Ptaszynska A
Lancet Diabetes Endocrinol
. 2015 Dec;
4(3):211-220.
PMID: 26620248
Background: Hypertension is a common comorbidity in patients with type 2 diabetes mellitus and a major risk factor for microvascular and macrovascular disease. Although the blood pressure-lowering effects of sodium-glucose...
6.
Ji L, Ma J, Li H, Mansfield T, Tjoen C, Iqbal N, et al.
Clin Ther
. 2014 Jan;
36(1):84-100.e9.
PMID: 24378206
Objective: Dapagliflozin is a highly selective, orally active inhibitor of renal sodium-glucose cotransporter 2 that reduces hyperglycemia by increasing urinary glucose excretion. The goal of this study was to evaluate...
7.
Bailey C, Gross J, Hennicken D, Iqbal N, Mansfield T, List J
BMC Med
. 2013 Feb;
11:43.
PMID: 23425012
Background: Management of type 2 diabetes with metformin often does not provide adequate glycemic control, thereby necessitating add-on treatment. In a 24-week clinical trial, dapagliflozin, an investigational sodium glucose cotransporter...
8.
Liu Y, Binz J, Numerick M, Dennis S, Luo G, Desai B, et al.
J Clin Invest
. 2003 Nov;
112(11):1678-87.
PMID: 14623915
Farnesoid X receptor (FXR) is a bile acid-activated transcription factor that is a member of the nuclear hormone receptor superfamily. Fxr-null mice exhibit a phenotype similar to Byler disease, an...
9.
Holt J, Luo G, Billin A, Bisi J, McNeill Y, Kozarsky K, et al.
Genes Dev
. 2003 Jun;
17(13):1581-91.
PMID: 12815072
The nuclear bile acid receptor FXR has been proposed to play a central role in the feedback repression of the gene encoding cholesterol 7 alpha-hydroxylase (CYP7A1), the first and rate-limiting...
10.
Lakkis M, Decristofaro M, Ahr H, Mansfield T
Expert Rev Mol Diagn
. 2002 Jul;
2(4):337-45.
PMID: 12138498
The application of advanced modern biomedical and chemical research technologies in the pharmaceutical industry has led to a significant increase in the number of potential drug targets and lead candidates....